Sresan Pharmaceutical Shut Down Over Toxic Syrup
Analysis based on 10 articles · First reported Oct 06, 2025 · Last updated Oct 14, 2025
The shutdown of Sresan Pharmaceuticals and the subsequent investigations by the India — Enforcement Directorate will negatively impact the pharmaceutical sector, particularly in India, due to increased regulatory scrutiny and potential loss of public trust. This event highlights the importance of stringent quality control in drug manufacturing, potentially leading to stricter regulations and higher compliance costs for other pharmaceutical companies.
The India — Tamil Nadu government has ordered the complete shutdown of Sresan Pharmaceuticals and revoked its manufacturing license after its cough syrup, Coldrif, was found to be dangerously adulterated with Diethylene Glycol (DEG), a toxic substance. This contamination is linked to the deaths of over 22 children in India — Madhya Pradesh. Investigations revealed over 300 critical and major violations of good manufacturing and laboratory practices at Sresan Pharmaceuticals. The owner, G. Ranganathan, was arrested by India — Madhya Pradesh police, and the India — Enforcement Directorate conducted raids on the company's premises as part of a money laundering probe. The India — Tamil Nadu government has also initiated comprehensive inspections of other drug manufacturing units in the state and suspended two drug inspectors for dereliction of duty. India — Madhya Pradesh and India — Uttar Pradesh have banned the sale of Coldrif, and the Union government has issued an advisory on judicious prescribing of cough syrups for children.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard